GlassScriptPhysician profile
Thomas A Kelly
NPI 1902902182
$11,111.59
in general payments reported to CMS, 2019-2025
33 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,127 · 2020: $1,377 · 2021: $529 · 2022: $1,105 · 2023: $786 · 2024: $1,023 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,978.50 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $390.67 | 2019-2024 | Xarelto |
| Shockwave Medical, INC | $382.27 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $370.84 | 2019-2024 | Pressurewire, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Novartis Pharmaceuticals Corporation | $347.65 | 2019-2025 | |
| Abiomed | $309.89 | 2022-2025 | Impella |
| Penumbra, INC. | $300.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $269.59 | 2019-2025 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $238.04 | 2019-2024 | Lifevest |
| Pfizer INC. | $205.93 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.47 | 2021-2024 | Jardiance |
| Zoll Circulation INC | $146.56 | 2023 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Medtronic, INC. | $119.14 | 2021-2023 | Onyx Frontier |
| Terumo Medical Corporation | $110.70 | 2023 | Heartrail, Glidewire, Metacross Otw |
| Chiesi USA, INC. | $107.12 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $93.96 | 2019-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $74.18 | 2019-2021 | |
| Esperion Therapeutics, INC. | $64.46 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.07 | 2022-2023 | |
| Philips North America LLC | $38.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.26 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $33.71 | 2024 | Arcalyst |
| Cvrx, INC. | $31.26 | 2022 | |
| Cardiovascular Systems INC. | $28.97 | 2019-2021 | |
| Irhythm Technologies, INC. | $26.06 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Resmed Corp | $23.11 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $21.77 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $21.37 | 2019 | |
| Lundbeck LLC | $20.62 | 2019 | |
| Edwards Lifesciences Corporation | $16.75 | 2023 | Sapien 3 Ultra Resilia |
| Gilead Sciences, INC. | $16.06 | 2019 | |
| Merck Sharp & Dohme LLC | $15.00 | 2021 | |
| Boston Scientific Corporation | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.